Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

Rickerthestockpicker Mar. 27 at 10:01 AM

$VKTX Very

0 · Reply

DG20 Mar. 27 at 9:49 AM

$VKTX Dont forget the Brian Lian PhD patented the use of VK2809/TRBs for treatment of fibrotic conditions (this never gets discussed). If VK2809 were effective in incurable fibrotic illness’s like scleroderma the value of that medicine would be multiples from here. The combo of VK2735/VK2809 could easily result in best in industry MASH resolution. The combination of both medications would ostensibly increase the effective patent life of VK2809 for MASH as well likely nearing 2040’s. In addition TRBs have much potential for the at risk patient with persistent bad cholesterol. Whatever company that partners/purchases Viking gets a potential metabolic powerhouse. https://patents.google.com/patent/US20240189332A1/en

1 · Reply

adei01 Mar. 27 at 9:07 AM

$VKTX 400

0 · Reply

Domo06 Mar. 27 at 8:15 AM

$VKTX 300

0 · Reply

Epin813 Mar. 27 at 6:45 AM

$VKTX 200

0 · Reply

Thomocat Mar. 27 at 6:24 AM

$VKTX actually its tomorrow, going all-in premarket

0 · Reply

Cacaos Mar. 27 at 3:38 AM

$VKTX wtf trend then not. Ok

0 · Reply

biolover Mar. 27 at 3:06 AM

$VKTX what is missing $PFE $AMGN have lousy assets. ..

2 · Reply

Cacaos Mar. 27 at 3:03 AM

$VKTX we are all Gluttons lfg

0 · Reply

Cacaos Mar. 27 at 2:57 AM

$VKTX

0 · Reply

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Mar 10, 2026, 1:10 PM EDT - 16 days ago

Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 5, 2026, 4:03 PM EST - 21 days ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Feb 23, 2026, 2:29 PM EST - 4 weeks ago

Viking Therapeutics Stock Gains Amid Obesity Drug Buzz

Feb 14, 2026, 8:44 AM EST - 5 weeks ago

Viking Therapeutics: Full-Speed Ahead

Feb 13, 2026, 8:35 AM EST - 5 weeks ago

Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential

Feb 12, 2026, 12:44 AM EST - 6 weeks ago

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 5:10 PM EST - 6 weeks ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 4:33 PM EST - 6 weeks ago

Viking Therapeutics Stock Climbs After Q4 Report: Details

Feb 11, 2026, 4:16 PM EST - 6 weeks ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 5, 2026, 6:03 PM EST - 7 weeks ago

The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short

Feb 4, 2026, 4:05 PM EST - 7 weeks ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 3, 2026, 1:27 PM EST - 7 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Jan 13, 2026, 1:35 AM EST - 2 months ago

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:19 PM EST - 2 months ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 2 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 2 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 2 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Jan 3, 2026, 10:00 AM EST - 2 months ago

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Jan 1, 2026, 2:13 AM EST - 3 months ago

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Dec 28, 2025, 9:40 AM EST - 3 months ago

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Dec 6, 2025, 8:57 AM EST - 3 months ago

Viking Therapeutics: Prepping For A Critical 2026

Nov 25, 2025, 4:05 PM EST - 4 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 1:58 PM EST - 4 months ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Nov 19, 2025, 4:48 AM EST - 4 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:55 AM EST - 4 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 5 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 5, 2025, 10:01 AM EST - 5 months ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Oct 29, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 23, 2025, 10:42 AM EDT - 5 months ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:05 AM EDT - 5 months ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 22, 2025, 7:33 PM EDT - 5 months ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 5 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 5 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 4, 2025, 9:44 AM EDT - 6 months ago

Viking Therapeutics: A Speculative Buy

Sep 28, 2025, 2:00 PM EDT - 6 months ago

Viking Therapeutics: Overdue For Gains

Sep 23, 2025, 1:53 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 22, 2025, 1:55 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 8, 2025, 5:43 PM EDT - 7 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 23, 2025, 6:57 AM EDT - 7 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Aug 20, 2025, 8:52 PM EDT - 7 months ago

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 9:50 AM EDT - 7 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 7 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 7 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 2:44 PM EDT - 7 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 1:45 PM EDT - 7 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 7 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Rickerthestockpicker Mar. 27 at 10:01 AM

$VKTX Very

0 · Reply

DG20 Mar. 27 at 9:49 AM

1 · Reply

adei01 Mar. 27 at 9:07 AM

$VKTX 400

0 · Reply

Domo06 Mar. 27 at 8:15 AM

$VKTX 300

0 · Reply

Epin813 Mar. 27 at 6:45 AM

$VKTX 200

0 · Reply

Thomocat Mar. 27 at 6:24 AM

$VKTX actually its tomorrow, going all-in premarket

0 · Reply

Cacaos Mar. 27 at 3:38 AM

$VKTX wtf trend then not. Ok

0 · Reply

biolover Mar. 27 at 3:06 AM

$VKTX what is missing $PFE $AMGN have lousy assets. ..

2 · Reply

Cacaos Mar. 27 at 3:03 AM

$VKTX we are all Gluttons lfg

0 · Reply

Cacaos Mar. 27 at 2:57 AM

$VKTX

0 · Reply

Xanderzzzzzzz Mar. 27 at 2:57 AM

$VKTX

0 · Reply

Ohzipit Mar. 27 at 2:21 AM

$VKTX tonight’s WSJ short article.

1 · Reply

DragonAlgo Mar. 27 at 1:31 AM

🐉 $VKTX CALL — DragonAlgo® Signal Contract: VKTX CALL Expiry: 2026-04-17 | Strike: $35.00 | Type: CALL Option Plan (premium): Entry: $2.17 Stop: $1.57 TP1: $2.83 TP2: $3.70 TP3: $5.22 🔗 https://dragonalgo.com

0 · Reply

Discovergems Mar. 27 at 1:25 AM

$MDGL buyout buzz and hopefully eventually someone does buys them is a very welcome development to likes of $VKTX and others…. All of sudden what Vikings put on hold could become a golden goose for the company through partnerships of just NASH asset

0 · Reply

Xanderzzzzzzz Mar. 27 at 1:19 AM

$VKTX

0 · Reply

Lets_Go_Brndn Mar. 27 at 1:18 AM

$VKTX This will be $80 to $100 by EOY.

1 · Reply

mikesterz7 Mar. 27 at 12:53 AM

$VKTX Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.

0 · Reply

biolover Mar. 27 at 12:00 AM

$VKTX the mdgl CEO is the biggest Empty leaker in history. This is third time. Extremely unlikely Lilly to acquire MDGL. Now good luck to mdgl holders. Could be another BP but not Lilly. If I am wrong on this it means Lilly is a paper tiger and would be overtaken in obesity.

0 · Reply

Xanderzzzzzzz Mar. 26 at 11:30 PM

$VKTX

0 · Reply

Alligator Mar. 26 at 10:57 PM

$VKTX Eli Lilly on MDGL? Huh….

0 · Reply

whiskyqueen Mar. 26 at 10:15 PM

$VKTX Very nice seeing Neil become the voice of the company that’s been needed for a loooong time. He knows this game as good as anyone 😊

0 · Reply

whiskyqueen Mar. 26 at 9:50 PM

$VKTX Anyone else catch this?

0 · Reply

Market Cap	3.84B
Revenue (ttm)	0.00
Net Income (ttm)	-359.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,558,600
Avg Vol	2,899,184
Day's Range	N/A - N/A
Shares Out	115.55M
Stochastic %K	54%
Beta	0.75
Analysts	Strong Sell
Price Target	$93.73